# HydroCision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hydrocision

- Industry: Medical Devices & Equipment
- Headquarters: Billerica, US
- Website: www.hydrocision.com
- Total disclosed funding: $20M
- Latest round: Series G (Dec 11, 2006)
- Investors on record: 4

## About

HydroCision Inc. develops advanced medical devices that utilize proprietary FluidJet technology, offering innovative solutions for minimally invasive surgical procedures in various medical fields.Founded in 1994 and headquartered in Billerica, US, HydroCision Inc. specializes in developing medical devices. The company has undergone strategic changes, including its focus on minimally invasive surgical solutions. HydroCision has successfully completed a total of 7 deals, with the most recent investment occurring on September 15, 2010, when it raised USD 12.70 mn in a Series G funding round led by Triathlon Medical Partners, with participation from Oxford Bioscience Partners, Rising Tide, and Zero Stage Capital. The CEO, Alain Tranchemontagne, oversees the company's strategic direction.HydroCision, Inc. specializes in the development and commercialization of innovative medical devices centered around its proprietary FluidJet technology. Its core product offerings include the TenJet and SpineJet systems, designed for minimally invasive surgical procedures using a high-velocity jet of sterile saline for targeted tissue resection and aspiration. The TenJet system treats soft tissue conditions, while the SpineJet system addresses spinal issues. HydroCision's technology is applicable in orthopedics, urology, and wound management, serving healthcare providers across North America and Europe.HydroCision generates revenue through direct sales of its medical devices to hospitals, outpatient surgical centers, and specialty clinics. The company's sales model is based on one-time transactions for its single-use products, including the TenJet and SpineJet systems. These devices are sold through direct relationships with healthcare providers and strategic partnerships with distributors, reflecting the advanced technology and clinical benefits of HydroCision’s offerings. Revenue growth is driven by increasing demand for minimally invasive surgical solutions that enhance patient outcomes and operational efficiency.HydroCision plans to leverage its recent funding from the USD 12.70 mn Series G round to innovate and expand its product line. The company is focused on launching new products that enhance its existing portfolio, with specific details on release dates to be announced. Additionally, HydroCision aims to expand its market presence in Europe and Asia by 2015, building upon its established relationships with healthcare providers. Recent growth financing from Volcano Capital, Bioventures, and Omega Funds will support these strategic initiatives.

## Funding rounds

- Series G, Dec 11, 2006, $13M — Oxford Bioscience Partners, Zero Stage Capital, Rising Tide, Triathlon Medical Partners
- Series B, Jun 4, 2001, $2M — Oxford Bioscience Partners
- Series B, Apr 24, 2001, $5.5M — Oxford Bioscience Partners, Zero Stage Capital, Rising Tide

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B, Series G
- Zero Stage Capital (https://capitalatlas.ai/funds/zero-stage-capital) — Series B, Series G
- Rising Tide — Series B, Series G
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series G